CYSTEAMINE BITARTRATE DELAYED-RELESEASE CAPSULES (RP103) COMPARED TO CYSTEAMINE

半胱胺酒石酸氢盐延迟释放胶囊 (RP103) 与半胱胺相比

• 批准号: 8166878
• 负责人: BRUCE A BARSHOP
• 金额: $ 1.95万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166878
• 关键词: Asses; Computer Retrieval of Information on Scientific Projects Database; Cystagon; Cysteamine; Cystinosis; Enrollment; Funding; Grant; Institution; Patients; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health; capsule; design

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Asses the PK, PD, safety and tolerability of RP103 compared to Cystagon in patients with nephropathic cystinosis. Patients taking Cystagon as part of their treatment for cystinosis will be enrolled into the study and results will be used to inform the design the confirmatory PK and pivotal PD study comparing RP103 to Cystagon.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 在肾病患者中，RP103的PK，PD，RP103的安全性和耐受性。 将囊肿作为囊肿病治疗的一部分的患者将被纳入研究，结果将用于为设计提供了确认性PK和关键PD研究，将RP103与Cystagon进行了比较。